SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is rallying following a significant order for its wafer-level burn-in systems from a major silicon photonics customer, signaling a transition toward high-volume production for AI data center infrastructure. The stock remains a heavily debated AI infrastructure play, with the community actively split between bulls betting on multi-year growth in chip testing demand and bears pointing to high valuation multiples relative to current revenue.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is experiencing a historic sell-off as a revenue miss and a shift in enterprise spending toward AI infrastructure over software and consulting trigger widespread investor concern. The community is actively debating whether the 25% drop is an extreme overreaction to a short-term spending shift or a fundamental breakdown of the company's long-term business model.

SK hynix, Inc. engages in the manufacture and sale of semiconductor products. Its products include dynamic random access memory, flash memory, complementary metal oxide semiconductor image sensor, and others. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is seeing intense volatility following its recent U.S. ADR debut, with the community fiercely debating whether the stock's significant premium over its South Korean listing signals a structural re-rating or a temporary bubble ripe for an arbitrage correction. Investors remain divided between bullish sentiment fueled by AI memory demand and HBM supply constraints, and bearish concerns regarding the impact of Korean market leverage, margin calls, and the potential for a technical rug-pull following the IPO excitement.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing intense volatility and downward pressure as investors weigh concerns over heavy capital expenditure and debt against its significant cloud and AI backlog. Community sentiment remains deeply divided, with some traders actively betting on a short squeeze or long-term value recovery, while others express frustration over the lack of communication from leadership during the ongoing slide.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending following an earnings report that featured strong revenue performance but left investors divided over the company's valuation and ARR growth expectations. While the community is actively debating whether the stock's massive rally is due for a healthy consolidation or if the cybersecurity sector remains a critical long-term AI infrastructure play, sentiment is split between those viewing the pullback as a buying opportunity and others concerned about its premium price-to-earnings multiple.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is currently trending as investors monitor its transition to a commercial-stage oncology company following the FDA approval of its breast cancer therapy, Revtorpyk. While the market is debating the short-term price action and potential for institutional buyouts, the community remains focused on the drug's strong efficacy data and the company's improved financial position to execute its commercial launch.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending following a strategic shift to discontinue internal drug discovery and close its Alabama facility, a move investors are interpreting as a potential catalyst for an acquisition or buyout. The community is actively debating the company's path to profitability, with many highlighting the stock's high short interest and debating whether this restructuring signals a sale or a long-term pivot to external innovation.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI is experiencing a surge in social media activity driven by anticipation of upcoming Phase 3 trial milestones and potential Russell 2000 index inclusion, which investors believe will bring significant institutional demand. The community is actively debating the stock's long-term valuation compared to sector peers and monitoring for signs of major pharma partnerships, while many remain focused on the potential for a gamma squeeze or a strategic re-rating.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors weigh recent platform developments and expansion efforts against persistent volatility, with the community actively debating whether current price levels represent a significant accumulation opportunity or continued downside risk. Discussion is centered on the potential impact of long-term infrastructure milestones and enterprise adoption, balanced against concerns regarding supply dilution and the need for sustained real-world usage.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2024 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is currently trending as speculative takeover interest intensifies, driven by market chatter linking the studio to potential acquirers like Legendary Entertainment. Investors and the community are actively debating the company's valuation against its deep content library, with many viewing the stock as an attractive acquisition target in a consolidating media landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma 

AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.

Genmab Announces TEPKINLY (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The...

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, and lenalidomide, compared to standard-of-care, rituximab plus gemcitabine...

Genmab Presents Promising Epcoritamab Data In Elderly DLBCL Patients

(RTTNews) - Genmab A/S (GMAB) reported positive findings from two clinical studies evaluating epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are not eligible for anthracycline-based chemotherapy...

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with diffuse large B-cell lymphoma (DLBCL) who may have limited treatment options due to advanced age or...

Genmab Reports Epcoritamab Benefits Across Relapsed Follicular Lymphoma Subgroups

(RTTNews) - Genmab A/S (GMAB) on Thursday presented new subgroup data from the Phase 3 EPCORE FL-1 trial showing that epcoritamab in combination with rituximab and lenalidomide (R2) delivered consistent efficacy and a manageable safety profile across multiple patient subgroups wi...

Genmab Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Genmab A/S (Nasdaq: GMAB) today announced new data from a post-hoc subgroup analysis from the pivotal Phase 3 EPCORE FL-1 trial, evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, in combination with rituximab and lenalidomide (epcoritamab + R2) in adult patients with...

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

Genmab A/S (Nasdaq: GMAB) announced today that 23 abstracts, including 20 abstracts evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, will be presented or published at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, from May 29-June 2...

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) have received an average recommendation of "Moderate Buy" from the twelve analysts that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and...

What is HC Wainwright's Forecast for Genmab A/S Q2 Earnings?

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Research analysts at HC Wainwright boosted their Q2 2026 earnings per share estimates for shares of Genmab A/S in a report released on Thursday, April 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings o...

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Genmab - ADR

Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$28.73
Prev Close	$28.80
Open	$28.83
Dividend Yield	0.00%
50-Day Moving Average	$26.47
Beta	0.65
Avg. Volume	1.68M
PE Ratio	21.51

52-Week High	$35.43
52-Week Low	$21.00
Market Capitalization	$17.13B
EPS (Annual)	$1.55
Price to Book	3.11
Revenue Per Employee	$1.23M

Feed

News

Sentiment

Earnings

Fundamentals

Info

GMABGenmab - ADR

Latest GMAB News